What are Therapeutic cancer vaccine drugs?

Therapeutic cancer vaccine drugs are pharmacologic agents that share a common mechanism (typically targeting Patient-specific tumor neoantigens). 4 are currently marketed, with 29 more in clinical development.

What are the marketed Therapeutic cancer vaccine drugs?

Marketed Therapeutic cancer vaccine drugs include D-cure, PCRA (Intermittent injection), CPA, VEC.

Therapeutic cancer vaccine

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

4 marketed 21 in Phase 3 6 in Phase 2 2 in Phase 1

This page covers all Therapeutic cancer vaccine drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Patient-specific tumor neoantigens, MUC1 (mucin 1) tumor-associated antigen, HER2 (human epidermal growth factor receptor 2).

Targets

Patient-specific tumor neoantigens · MUC1 (mucin 1) tumor-associated antigen · HER2 (human epidermal growth factor receptor 2) · GM2 ganglioside · ras and CEA (carcinoembryonic antigen) · MAGE-1, MAGE-3 (melanoma-associated antigens) · WT1 (Wilms tumor antigen 1) · Tumor-associated antigens presented via Hsp96 complexes · Myeloma immunoglobulin idiotype (patient-specific) · Tumor-associated antigens (TAAs)

Marketed (4)

D-cure · KU Leuven · Oncology
D-cure is a therapeutic vaccine designed to stimulate the immune system to recognize and eliminate cancer cells expressing specific tumor-associated antigens.
PCRA (Intermittent injection) · Örebro University, Sweden · Oncology
PCRA is a peptide-based immunotherapeutic that stimulates the patient's own immune system to recognize and attack cancer cells.
CPA · ImmunoVaccine Technologies, Inc. (IMV Inc.) · Oncology
CPA is a cancer immunotherapy vaccine that stimulates the immune system to recognize and attack cancer cells by presenting tumor-associated antigens.
VEC · Centre Leon Berard · Oncology
VEC is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.

Phase 3 pipeline (21)

TAK-019 · Takeda · Oncology
TAK-019 is a therapeutic vaccine designed to stimulate immune responses against cancer cells expressing specific tumor-associated antigens.
Tecemotide (L-BLP25) · Merck KGaA, Darmstadt, Germany · Oncology
Tecemotide is a cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing MUC1 antigen.
Begrivac® · Chiltern Pesquisa Clinica Ltda · Oncology
Begrivac is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.
GC3110A vaccine · Green Cross Corporation · Oncology
GC3110A is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.
irradiated RBC · Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Oncology / Immunology
Irradiated red blood cells act as an immunogenic cellular vaccine to stimulate anti-tumor immune responses.
NeuVax™ vaccine · Galena Biopharma, Inc. · Oncology
NeuVax is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing the HER2 protein.
GM2-KLH vaccine · European Organisation for Research and Treatment of Cancer - EORTC · Oncology
GM2-KLH vaccine stimulates the immune system to recognize and attack cancer cells expressing the GM2 ganglioside antigen on their surface.
GSK208141 vaccine · GlaxoSmithKline · Oncology
GSK208141 is a therapeutic vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.
GC3110B vaccine · Green Cross Corporation · Oncology
GC3110B is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.
Dendritic Cell Vaccine · Fundacion Clinic per a la Recerca Biomédica · Oncology
A dendritic cell vaccine that activates the patient's immune system to recognize and attack cancer cells by presenting tumor-associated antigens.
Corynebacterium granulosum P40 · Centro Oncologico de Excelencia · Oncology
Corynebacterium granulosum P40 is a bacterial immunotherapeutic that stimulates anti-tumor immune responses through activation of innate and adaptive immunity.
PANVAC™-VF · Therion Biologics Corporation · Oncology
PANVAC-VF is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing ras and CEA tumor-associated antigens.
CancerVax vaccine (CANVAXIN) · CancerVax Corporation · Oncology
CANVAXIN is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.
Mevac-A vaccine · Chiang Mai University · Oncology
Mevac-A is a therapeutic vaccine designed to stimulate immune responses against mevalonate pathway-associated antigens to treat cancer.
OSE2101 · GERCOR - Multidisciplinary Oncology Cooperative Group · Oncology
OSE2101 is a therapeutic cancer vaccine that targets WT1 (Wilms tumor antigen 1) to activate the immune system against WT1-expressing tumor cells.
HSPPC-96 or Oncophage · Agenus Inc. · Oncology
HSPPC-96 is a personalized cancer vaccine that uses heat shock protein-peptide complexes derived from a patient's own tumor to stimulate immune recognition and destruction of cancer cells.
SK-PC-B70M · SK Chemicals Co., Ltd. · Oncology
SK-PC-B70M is a therapeutic cancer vaccine designed to stimulate immune responses against tumor-associated antigens.
HAPREP® · National Cancer Center, Korea · Oncology
HAPREP is a therapeutic cancer vaccine that primes the immune system to recognize and attack cancer cells expressing shared tumor-associated antigens.
Myeloma Immunoglobulin Idiotype Vaccine-KLH · National Cancer Institute (NCI) · Oncology
This vaccine trains the immune system to recognize and attack cancer cells by targeting the unique protein signature (idiotype) present on individual myeloma tumors.
MSB0010718C · Istituto Oncologico Veneto IRCCS · Oncology
MSB0010718C is a therapeutic cancer vaccine designed to activate the immune system against tumor-associated antigens.
MR-Vac · GlaxoSmithKline · Oncology
MR-Vac is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.

Phase 2 pipeline (6)

ACE393 · TD Vaccines A/S · Oncology
ACE393 is a therapeutic vaccine designed to stimulate immune responses against cancer cells by targeting tumor-associated antigens.
APC8015F · Dendreon · Oncology
APC8015F is a therapeutic cancer vaccine designed to stimulate an immune response against prostate cancer cells.
Autologous DC vaccine · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Oncology
Stimulates an immune response against cancer cells
HerpV and QS-21 · Agenus Inc. · Oncology
Stimulates the immune system by activating CD4+ T cells through the QS-21 adjuvant
GEN-004 with Aluminum Hydroxide Adjuvant · Genocea Biosciences, Inc. · Oncology
GEN-004 is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack tumor-associated antigens expressed on cancer cells.
Axalimogene filolisbac · Advaxis, Inc. · Oncology
Lysosomal targeting of tumor cells via Listeria monocytogenes

Phase 1 pipeline (2)

ADXS31-142 · Advaxis, Inc. · Oncology
Listeria monocytogenes-based immunotherapy targeting MUC1
ADXS31-164 · Advaxis, Inc. · Oncology
Listeria monocytogenes-based immunotherapy targeting MUC1

Patent intelligence

cancer vaccine patent landscape — aggregated cliff calendar, attackable patents, originator estates